KPKoralia Paschalaki

Koralia Paschalaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Koralia Paschalaki has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2: relevance for gut angiodysplasia

    by Adela Constantinescu-Bercu, Koval E. Smith, Shuo Yi Wong, Mattia Ballerini, Alessia Nastro, Benjamin G. Wiggins, Daniela Pirri, Yucheng Li, Juun Evers, Olga Tsiamita, et al.

    Management of recurrent gastrointestinal (GI) bleeding is a clinical unmet need for patients with von Willebrand disease (VWD) and is linked to the presence of gut vascular malformations (angiodysplasia). We previously demonstrated that von Willebrand factor (VWF) regulates angiogenesis and vascular integrity. VWF controls the storage of the angiogenesis regulator angiopoietin-2 (Angpt-2) in endothelial cells (EC), suggesting a candidate for the genesis of angiodysplasia; however, no direct evidence of the role of Angpt-2 in VWF-dependent angiogenesis is available. Using VWF-deficient human umbilical vein EC (HUVEC) and endothelial colony-forming cells (ECFCs) from patients with severe VWD, we found that loss of VWF resulted in increased Angpt-2 expression through the positive feedback loop Angpt-2–Tie-2–Akt–FOXO1–Angpt-2. In the gut of VWF-deficient mice, Angpt-2 expression was increased, whereas Angpt-1 expression was decreased, suggesting that VWF regulates the Angpt/Tie2 balance in the gut. Moreover, the intestinal vasculature in the jejunum of VWF-deficient mice appeared abnormal, with hypersprouting and lumen formation defects. The findings reveal VWF-deficient mice as a model to study gut angiodysplasia. We investigated sprouting angiogenesis in vitro using a fibrin bead assay and found increased sprouting in VWF-deficient EC. We developed a 3-dimensional microfluidic model of angiogenesis and found that ECFCs from patients with severe VWD exhibit defective remodeling and abnormal lumen formation, reminiscent of the defects in the gut of VWF-deficient mice. Importantly, inhibition of Angpt-2 reduced sprouting in VWF-deficient HUVEC and normalized vascular remodeling in VWD-ECFCs, suggesting that Angpt-2 inhibitors may be effective in patients with VWD with GI bleeding and angiodysplasia.


  • Open Access

    Loss of ERG function causes lymphatic vessel malformations and primary lymphoedema

    by Daniela Pirri, Hannah Maude, Astrid Stroobants, Kazim Ogmem, Ege Sackey, Sara Dobbins, Dionysios Grigoriadis, Juan Carlos Del Rey Jimenez, Dana E Al-Ansari, Karen Frudd, et al.

    Transcription factor networks are crucial for the regulation of endothelial cell gene expression during vascular development and homeostasis. A recent analysis of 269 rare diseases in 77,539 individuals revealed an association between loss-of-function variants in ERG, encoding an ETS transcription factor, with primary lymphoedema. However, the pathogenicity of such variants and possible mechanisms of ERG-associated lymphatic vessel dysfunction remains to be established. Here, we have further identified and characterised lymphoedema-associated ERG genetic variants, revealing pathogenic mechanisms ranging from differential ERG subcellular localisation to altered DNA-binding and impaired transactivation. We confirm a role for ERG in regulating lymphangiogenesis using in vitro assays and a lymphatic endothelium-specific Erg deletion mouse model. Furthermore, we characterise the transcriptional and epigenomic landscape of human dermal lymphatic endothelial cells, identifying a unique role for ERG in regulating lymphatic gene programs, including the establishment of cooperative TF networks with PROX1 and GATA2. Our studies identify ERG as a master regulator of lymphatic endothelial cell transcriptional networks and uncover the mechanisms that underpin a novel causative gene for primary lymphoedema.


  • Isolation and Characterization of Endothelial-Colony Forming Cells (ECFC): Studying Endothelial Senescence for Translational Studies and for Personalized Medicine

    by Koralia Paschalaki, Charis Pericleous

    Endothelium regulates vascular homeostasis maintaining a healthy cardiovascular system but also plays a key role in tumor development, progression, and metastasis. Endothelial senescence can be driven by aging, DNA damage, oxidative stress, oncogenes and chemotherapy, and contributes to vascular dysfunction. Endothelial colony-forming cells (ECFC) are endothelial-committed progenitors with clonogenic potential, de novo angiogenic capacity and endothelial regenerative abilities. Studying ECFC senescence provides a novel approach to investigate the molecular mechanisms of endothelial dysfunction and response to treatment, in a noninvasive and personalized manner.


  • Endothelial progenitors exhibit a senescent and prothrombotic phenotype post COVID-19 disease

    by Koralia Paschalaki, Daisy Gresham, Anand Shah, Peter Kelleher, Anna Reed, Aran Singanayagam, Vassilis Gorgoulis, Peter J. Barnes, Anna Randi, Charis Pericleous, et al.

    Background: COVID-19 is associated with long-term risk of cardiovascular disease (CVD), particularly after severe disease. The long-term consequences of SARS-CoV-2 infection on endothelium are poorly understood. Senescent endothelial cells are dysfunctional, exhibit a proinflammatory ‘senescence-associated-secretory-phenotype’ (SASP) and promote CVD. We hypothesised that endothelium post-COVID is senescent and dysfunctional, promoting cardiovascular comorbidities. Methods: Endothelial colony forming cells (ECFC) are circulating endothelial progenitors and provide non-invasive access to endothelial cells. We collected blood samples from individuals who recovered from COVID-19 (n=6, 8-13 months post infection, 5 had critical disease) and age-matched healthy controls for ECFC isolation. ECFC were characterised for endothelial markers, proliferation, senescence and selected SASP mediators by immunofluorescence (IF). We used a high-throughput ‘organ-on-a-chip’ microfluidic platform (OrganoPlate-MIMETAS) that allows formation of microvessels for functional and IF analysis. Results: Post-COVID ECFC exhibited reduced proliferation (Ki-67), increased expression of senescence markers (senescence-associated-β-galactosidase activity, p21), IFN-γ-inducible-protein-10, plasminogen activator inhibitor-1 and von Willebrand Factor compared to control ECFC. In 3D cultures maintained for 14 days, microvessels formed with post-COVID ECFC showed increased permeability and disruption of endothelial junctions. Conclusion: We demonstrate that ECFC from patients post-COVID exhibit a dysfunctional, senescent and prothrombotic phenotype that may contribute to the increased risk of cardiovascular comorbidities.


  • Open Access

    Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD

    by Koralia Paschalaki, Christos Rossios, Charis Pericleous, Mairi MacLeod, Stephen Rothery, Gavin C Donaldson, Jadwiga A Wedzicha, Vassilis Gorgoulis, Anna M Randi, Peter J Barnes

    Cellular senescence contributes to the pathophysiology of chronic obstructive pulmonary disease (COPD) and cardiovascular disease. Using endothelial colony-forming-cells (ECFC), we have demonstrated accelerated senescence in smokers and patients with COPD compared with non-smokers. Subgroup analysis suggests that ECFC from patients with COPD on inhaled corticosteroids (ICS) (n=14; eight on ICS) exhibited significantly reduced senescence (Senescence-associated-beta galactosidase activity, p21CIP1), markers of DNA damage response (DDR) and IFN-γ-inducible-protein-10 compared with patients with COPD not on ICS. In vitro studies using human-umbilical-vein-endothelial-cells showed a protective effect of ICS on the DDR, senescence and apoptosis caused by oxidative stress, suggesting a protective molecular mechanism of action of corticosteroids on endothelium.


  • Alveolar type II cells harbouring SARS-CoV-2 show senescence with a proinflammatory phenotype

    by Koralia Paschalaki, Konstantinos Evangelou, Dimitris Veroutis, Periklis Foukas, Christos Kittas, Athanasios Tzioufas, Laurence De Leval, Demetris Vassilakos, Peter Barnes, Vassilis Gorgoulis

    Background: COVID-19 disease primarily affects the respiratory system but can evolve to a multisystem inflammatory syndrome. Increased mortality is observed in elderly and in patients with age-related comorbidities. Cellular senescence is characterised by cell-cycle arrest and a proinflammatory ‘Senescence-Associated-Secretory-Phenotype’ (SASP). Viral infection has been associated with senescence. We have studied whether SARS-CoV-2 may be associated with senescence and the SASP phenotype. Methods: Lung tissues from ten COVID-19 and ten age-matched control patients were analysed by immunohistochemistry for: SARS-CoV-2, ACE-2, TTF-1, CD68, p16INK4, IL-1β, IL-6 and the novel cellular senescence marker SenTraGor. Results: SARS-CoV-2 was detected in alveolar type-II (AT2) pneumocytes of all COVID-19 patients using a monoclonal antibody we developed against the spike protein. Electron microscopy confirmed the presence of the virus within AT2 cells. We observed that a proportion of SARS-CoV-2 AT2 infected cells exerted features of senescence, displaying strong reactivity to SenTraGor. Senescent phenotype was further confirmed with p16INK4 co-staining. Subsequently, we found that SenTraGor-positive cells in COVID-19 samples co-expressed IL-1β and IL-6, which were absent in non-COVID-19 cases. Conclusion: This is the first evidence of senescence and expression of SASP components in SARS-CoV-2 infected human lung cells. Further studies need to determine whether senescence pre-exists at the time of infection, making cells susceptible to the virus, or is triggered as an antiviral response. Our findings justify the application of senotherapeutics for treatment or prevention of COVID-19 patients.


  • Inhaled corticosteroids reduce senescence in endothelial progenitor cells from COPD patients

    by Koralia Paschalaki, Christos Rossios, Vassilis Gorgoulis, Anna Randi, Pater Barnes

    Background: Cellular senescence drives the pathophysiology of COPD and cardiovascular disease (CVD) and is a promising therapeutic target. Senescent endothelial cells are dysfunctional, exhibit a proinflammatory ‘senescence-associated-secretory-phenotype’ (SASP) and promote atherosclerosis. We have demonstrated accelerated endothelial senescence in smokers and COPD patients (Paschalaki et al, Stem Cells 2013). Inhaled corticosteroids (ICS) appear to have a protective effect on CVD in COPD, but the mechanism is unknown. We investigated whether ICS in COPD have a protective effect on senescence and SASP in endothelial progenitors, named endothelial-colony-forming-cells (ECFC). Methods: ECFC were isolated from healthy non-smokers, smokers and COPD patients. Markers of senescence, DNA damage response (DDR), apoptosis and secreted cytokines were measured. Results: ECFC from smokers and COPD patients displayed increased markers of senescence and DDR compared to non-smokers, measured by Senescence-associated-β-galactosidase (SA-β-gal), p21CIP1, p16INK4, 53BP1 and γ-H2AX. Subgroup analysis of the data shows that ECFC from COPD patients on ICS exhibit reduced senescence and IFN-γ-inducible-protein 10 compared to COPD patients not on ICS. In vitro experiments on endothelial cells under oxidant-conditions to induce premature-senescence, in the absence or presence of increasing doses of the ICS budesonide, demonstrated reduced markers of senescence, DDR and apoptosis. Conclusion: Our data suggest that ICS suppress senescence and the SASP in endothelial progenitors from COPD patients and propose a novel and protective molecular mechanism of action of corticosteroids on endothelium and possibly on CVD.


  • Open Access

    Recent Advances in Endothelial Colony Forming Cells Toward Their Use in Clinical Translation

    by Koralia E. Paschalaki, Anna M. Randi

    The term “Endothelial progenitor cell” (EPC) has been used to describe multiple cell populations that express endothelial surface makers and promote vascularisation. However, the only population that has all the characteristics of a real “EPC” is the Endothelial Colony Forming Cells (ECFC). ECFC possess clonal proliferative potential, display endothelial and not myeloid cell surface markers, and exhibit pronounced postnatal vascularisation ability in vivo. ECFC have been used to investigate endothelial molecular dysfunction in several diseases, as they give access to endothelial cells from patients in a non-invasive way. ECFC also represent a promising tool for revascularization of damaged tissue. Here we review the translational applications of ECFC research. We discuss studies which have used ECFC to investigate molecular endothelial abnormalities in several diseases and review the evidence supporting the use of ECFC for autologous cell therapy, gene therapy and tissue regeneration. Finally, we discuss ways to improve the therapeutic efficacy of ECFC in clinical applications, as well as the challenges that must be overcome to use ECFC in clinical trials for regenerative approaches.


  • Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and Patients with Chronic Obstructive Pulmonary Disease

    by Koralia E. Paschalaki, Anna Zampetaki, Jonathan R. Baker, Mark A. Birrell, Richard D. Starke, Maria G. Belvisi, Louise E. Donnelly, Manuel Mayr, Anna M. Randi, Peter J. Barnes


  • Open Access

    Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes

    by Inês G. Mollet, Dilipkumar Patel, Fatima S. Govani, Adam Giess, Koralia Paschalaki, Manikandan Periyasamy, Elaine C. Lidington, Justin C. Mason, Michael D. Jones, Laurence Game, et al.

    Spontaneous reports from patients able to report vascular sequelae in real time, and recognition that serum non transferrin bound iron may reach or exceed 10μmol/L in the blood stream after iron tablets or infusions, led us to hypothesize that conventional iron treatments may provoke acute vascular injury. This prompted us to examine whether a phenotype could be observed in normal human endothelial cells treated with low dose iron. Confluent primary human endothelial cells (EC) were treated with filter-sterilized iron (II) citrate or fresh media for RNA sequencing and validation studies. RNA transcript profiles were evaluated using directional RNA sequencing with no pre-specification of target sequences. Alignments were counted for exons and junctions of the gene strand only, blinded to treatment types. Rapid changes in RNA transcript profiles were observed in endothelial cells treated with 10μmol/L iron (II) citrate, compared to media-treated cells. Clustering for Gene Ontology (GO) performed on all differentially expressed genes revealed significant differences in biological process terms between iron and media-treated EC, whereas 10 sets of an equivalent number of randomly selected genes from the respective EC gene datasets showed no significant differences in any GO terms. After 1 hour, differentially expressed genes clustered to vesicle mediated transport, protein catabolism, and cell cycle (Benjamini p = 0.0016, 0.0024 and 0.0032 respectively), and by 6 hours, to cellular response to DNA damage stimulus most significantly through DNA repair genes FANCG, BLM, and H2AFX. Comet assays demonstrated that 10μM iron treatment elicited DNA damage within 1 hour. This was accompanied by a brisk DNA damage response pulse, as ascertained by the development of DNA damage response (DDR) foci, and p53 stabilization. These data suggest that low dose iron treatments are sufficient to modify the vascular endothelium, and induce a DNA damage response.